Collegium Pharmaceutical (COLL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

COLL · Stock Price

USD 39.33+10.44 (+36.14%)

Market Cap: $1.3B

Historical price data

Market Cap: $1.3BPipeline: 3 drugs (2 Phase 3)Patents: 20Founded: 2002HQ: Stoughton, United States

Sector Ranking#42 in Drug Delivery & Formulation #168 in Small Molecule Drugs

Overview

Collegium Pharmaceutical is a publicly traded, commercial-stage biopharmaceutical company with a strategic focus on pain management and neuropsychiatry. The company has established itself through a disciplined strategy of portfolio diversification, specializing in abuse-deterrent formulations and the acquisition/commercialization of differentiated medicines. Under new leadership, Collegium is executing on a growth trajectory, aiming to strengthen its position in ADHD and expand its impact through a commitment to science, corporate responsibility, and robust commercial execution.

Pain ManagementNeuropsychiatry

Technology Platform

An integrated commercial and regulatory operating model specializing in abuse-deterrent drug delivery, lifecycle management, and strategic acquisition/commercialization of differentiated pharmaceutical products.

Pipeline

3

3 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Xtampza ER (oxycodone)	Chronic Pain	Approved
HLD200 methylphenidate hydrochloride capsules + Placebo HLD2...	Attention Deficit Hyperactivity Disorder	Phase 3
Oxycodone DETERx + Placebo	Chronic Low Back Pain	Phase 3

Funding History

3

Total raised:$50M

IPOUndisclosedUndisclosedMay 7, 2015

Series B$30MUndisclosedJun 15, 2005

Series A$20MUndisclosedJun 15, 2003

FDA Approved Drugs

1

XTAMPZA ERNDAApr 26, 2016

Opportunities

Significant growth opportunity in the ADHD market through the commercialization of JORNAY PM and the pending acquisition of AZSTARYS, which diversifies revenue and leverages existing commercial infrastructure.

The ongoing shift towards abuse-deterrent opioid formulations in pain management provides a regulatory and market tailwind for the company's core pain portfolio.

Risk Factors

Exposure to extensive opioid-related litigation and regulatory headwinds that could impact the pain management market.

Revenue concentration in a limited number of products creates vulnerability to generic competition and loss of exclusivity.

Execution risk associated with integrating new acquisitions like AZSTARYS and achieving expected commercial synergies.

Competitive Landscape

Faces intense competition in both pain management (from other ADF opioid manufacturers and generics) and ADHD (from large pharma and numerous specialty players). Collegium's competitive edge lies in its specialized commercial and regulatory platform focused on abuse-deterrent technologies and lifecycle management of differentiated products.